Summary: | Introduction:Chronichemodialysisaimstoreplacerenalfunctionandprovidesanextensionoflifeexpectancy,however,complications dooccurandtheycan be seriousevenfatal.Knowingthe complicationscan enableabetterprognosticevaluationanduseofan interventionapproach.Thesecanbeidentifiedwhenperforminganamnesisandphysicalexamination, aswellas,withgreater precision,bymeansofrenalandcardiacbiomarkersandimagingtests.Objectives: toidentifyvalidbloodbiomarkerstodetectheartfailureandkidneyfailureassociatedwithkidneydiseaseand hemodialysis.Methods:systematicliteraturereviewconductedinAugust2018inthefollowing:WebOfScience,PubMed,Scopus,Cinahal, Cochrane,ScienceDirectandLilacs.Theguidingquestionwas:“Whatarethebloodbiomarkersusedtodetectheartfailureand kidneyfailure?”Atotalof537publicationswerefound,94oftheseappearedmorethanonce,383wereexcludedafterreadingtitles andabstracts,32wereexcludedafterreadingthefulltexts,and10wereexcludedinthequantitativeandqualitativesynthesis. Results:18paperscomposethefinalsampleandreportlaboratoryandimagingtests,instrumentstoassesstheriskofkidneyand heartfailure,andalsoclinicalmanagementoftheprogressionofkidneyandheartfailure.Allthestudiescorrelatedriskofmortality anddeathoutcome.Conclusion:laboratorytestsareimportanttoidentifyingkidneyandheartfailureandneedtobeusedtoimproveclinicalmanagementofthehemodialysistreatmentofpeoplewithchronickidneydiseaseinordertoimprovequalityoflifeandlifeexpectancy
|